Adhera Therapeutics, Inc. (ATRX)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2022 | 8.55 Million USD | 29.85% |
| 2021 | 6.58 Million USD | 4.27% |
| 2020 | 6.31 Million USD | 19.64% |
| 2019 | 5.28 Million USD | 234.75% |
| 2018 | -3.91 Million USD | -317.7% |
| 2017 | 1.79 Million USD | 209.98% |
| 2016 | 580.65 Thousand USD | 181.78% |
| 2015 | -710 Thousand USD | 61.07% |
| 2014 | -1.82 Million USD | -355.46% |
| 2013 | 714 Thousand USD | -42.14% |
| 2012 | 1.23 Million USD | 226.43% |
| 2011 | -976 Thousand USD | 8.44% |
| 2010 | -1.06 Million USD | -147.33% |
| 2009 | -431 Thousand USD | -110.66% |
| 2008 | 4.04 Million USD | 123.82% |
| 2007 | -16.97 Million USD | -1.08% |
| 2006 | -16.79 Million USD | 20.64% |
| 2005 | -21.16 Million USD | -49.13% |
| 2004 | -14.19 Million USD | -76.21% |
| 2003 | -8.05 Million USD | -482.01% |
| 2002 | -1.38 Million USD | 88.2% |
| 2001 | -11.73 Million USD | -87.5% |
| 2000 | -6.25 Million USD | 41.53% |
| 1999 | -10.7 Million USD | 54.47% |
| 1998 | -23.5 Million USD | 7.0% |
| 1997 | -25.27 Million USD | -461.56% |
| 1996 | -4.5 Million USD | -21.62% |
| 1995 | -3.7 Million USD | -42.31% |
| 1994 | -2.6 Million USD | -966.67% |
| 1993 | 300 Thousand USD | 30.43% |
| 1992 | 230 Thousand USD | 53.33% |
| 1991 | 150 Thousand USD | 650.0% |
| 1990 | 20 Thousand USD | -94.59% |
| 1989 | 370 Thousand USD | 294.74% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 Q1 | 9.55 Million USD | 11.74% |
| 2023 Q3 | 10.79 Million USD | 2.5% |
| 2023 Q2 | 10.53 Million USD | 10.21% |
| 2022 Q1 | 6.78 Million USD | 3.05% |
| 2022 Q3 | 7.85 Million USD | 20.96% |
| 2022 FY | 8.55 Million USD | 29.85% |
| 2022 Q2 | 6.49 Million USD | -4.29% |
| 2022 Q4 | 8.55 Million USD | 8.83% |
| 2021 Q1 | 6.39 Million USD | 1.19% |
| 2021 Q3 | 6.38 Million USD | -0.99% |
| 2021 Q4 | 6.58 Million USD | 3.12% |
| 2021 FY | 6.58 Million USD | 4.27% |
| 2021 Q2 | 6.45 Million USD | 0.94% |
| 2020 FY | 6.31 Million USD | 19.64% |
| 2020 Q1 | 5.73 Million USD | 8.52% |
| 2020 Q2 | 6.13 Million USD | 7.07% |
| 2020 Q3 | 6.25 Million USD | 1.94% |
| 2020 Q4 | 6.31 Million USD | 1.01% |
| 2019 Q2 | -199 Thousand USD | 87.66% |
| 2019 FY | 5.28 Million USD | 234.75% |
| 2019 Q1 | -1.61 Million USD | 58.83% |
| 2019 Q4 | 5.28 Million USD | 101.22% |
| 2019 Q3 | 2.62 Million USD | 1418.59% |
| 2018 FY | -3.91 Million USD | -317.7% |
| 2018 Q2 | -8.35 Million USD | -517.03% |
| 2018 Q1 | 2 Million USD | 11.3% |
| 2018 Q3 | -6.5 Million USD | 22.12% |
| 2018 Q4 | -3.91 Million USD | 39.78% |
| 2017 Q2 | 1.2 Million USD | 72.41% |
| 2017 Q1 | 700.82 Thousand USD | 20.7% |
| 2017 Q4 | 1.79 Million USD | 20.77% |
| 2017 Q3 | 1.49 Million USD | 23.34% |
| 2017 FY | 1.79 Million USD | 209.98% |
| 2016 Q1 | -307 Thousand USD | 56.76% |
| 2016 Q2 | -21 Thousand USD | 93.16% |
| 2016 Q3 | 227 Thousand USD | 1180.95% |
| 2016 Q4 | 580.65 Thousand USD | 155.79% |
| 2016 FY | 580.65 Thousand USD | 181.78% |
| 2015 Q2 | -726 Thousand USD | 37.58% |
| 2015 Q3 | -1.31 Million USD | -80.85% |
| 2015 Q4 | -710 Thousand USD | 45.93% |
| 2015 Q1 | -1.16 Million USD | 36.24% |
| 2015 FY | -710 Thousand USD | 61.07% |
| 2014 Q2 | -4.31 Million USD | 21.78% |
| 2014 Q4 | -1.82 Million USD | 43.05% |
| 2014 FY | -1.82 Million USD | -355.46% |
| 2014 Q1 | -5.51 Million USD | -872.41% |
| 2014 Q3 | -3.2 Million USD | 25.75% |
| 2013 FY | 714 Thousand USD | -42.14% |
| 2013 Q4 | 714 Thousand USD | -39.18% |
| 2013 Q3 | 1.17 Million USD | -17.21% |
| 2013 Q2 | 1.41 Million USD | -18.27% |
| 2013 Q1 | 1.73 Million USD | 40.6% |
| 2012 Q1 | 322 Thousand USD | 132.99% |
| 2012 Q2 | 1.29 Million USD | 300.62% |
| 2012 FY | 1.23 Million USD | 226.43% |
| 2012 Q3 | 788 Thousand USD | -38.91% |
| 2012 Q4 | 1.23 Million USD | 56.6% |
| 2011 Q3 | -1.04 Million USD | 77.81% |
| 2011 Q1 | -1.12 Million USD | -5.44% |
| 2011 FY | -976 Thousand USD | 8.44% |
| 2011 Q2 | -4.7 Million USD | -318.59% |
| 2011 Q4 | -976 Thousand USD | 6.51% |
| 2010 Q1 | -2.63 Million USD | -510.21% |
| 2010 FY | -1.06 Million USD | -147.33% |
| 2010 Q4 | -1.06 Million USD | -147.33% |
| 2010 Q3 | -431 Thousand USD | -146.29% |
| 2010 Q2 | 931 Thousand USD | 135.4% |
| 2009 FY | -431 Thousand USD | -110.66% |
| 2009 Q1 | -3.7 Million USD | -191.69% |
| 2009 Q2 | -7.92 Million USD | -113.7% |
| 2009 Q3 | -3.43 Million USD | 56.71% |
| 2009 Q4 | -431 Thousand USD | 87.44% |
| 2008 Q1 | -6.26 Million USD | 63.12% |
| 2008 Q4 | 4.04 Million USD | 291.71% |
| 2008 FY | 4.04 Million USD | 123.82% |
| 2008 Q3 | -2.11 Million USD | 74.89% |
| 2008 Q2 | -8.4 Million USD | -34.17% |
| 2007 Q1 | -38.18 Million USD | -127.31% |
| 2007 Q2 | -40.68 Million USD | -6.56% |
| 2007 Q3 | -29.33 Million USD | 27.91% |
| 2007 Q4 | -16.97 Million USD | 42.12% |
| 2007 FY | -16.97 Million USD | -1.08% |
| 2006 Q1 | -15.43 Million USD | 27.09% |
| 2006 Q4 | -16.79 Million USD | -46.99% |
| 2006 FY | -16.79 Million USD | 20.64% |
| 2006 Q2 | -20.36 Million USD | -31.94% |
| 2006 Q3 | -11.42 Million USD | 43.88% |
| 2005 Q4 | -21.16 Million USD | -91.22% |
| 2005 FY | -21.16 Million USD | -49.13% |
| 2005 Q3 | -11.07 Million USD | -58.78% |
| 2005 Q2 | -6.97 Million USD | 53.86% |
| 2005 Q1 | -15.11 Million USD | -6.45% |
| 2004 FY | -14.19 Million USD | -76.21% |
| 2004 Q4 | -14.19 Million USD | -592.39% |
| 2004 Q3 | -2.05 Million USD | 57.88% |
| 2004 Q2 | -4.86 Million USD | -1988.84% |
| 2004 Q1 | -233 Thousand USD | 97.11% |
| 2003 Q1 | -9.65 Million USD | -597.54% |
| 2003 Q2 | -8.06 Million USD | 16.47% |
| 2003 FY | -8.05 Million USD | -482.01% |
| 2003 Q4 | -8.05 Million USD | 45.43% |
| 2003 Q3 | -14.76 Million USD | -83.04% |
| 2002 Q3 | -6.44 Million USD | 65.21% |
| 2002 Q2 | -18.51 Million USD | -5.08% |
| 2002 Q1 | -17.61 Million USD | -50.19% |
| 2002 FY | -1.38 Million USD | 88.2% |
| 2002 Q4 | -1.38 Million USD | 78.51% |
| 2001 Q2 | -7.59 Million USD | 12.93% |
| 2001 FY | -11.73 Million USD | -87.5% |
| 2001 Q4 | -11.73 Million USD | -64.08% |
| 2001 Q3 | -7.14 Million USD | 5.92% |
| 2001 Q1 | -8.72 Million USD | -39.5% |
| 2000 Q3 | -7.89 Million USD | 18.21% |
| 2000 Q1 | -10.72 Million USD | -0.19% |
| 2000 FY | -6.25 Million USD | 41.53% |
| 2000 Q4 | -6.25 Million USD | 20.77% |
| 2000 Q2 | -9.65 Million USD | 9.94% |
| 1999 Q2 | -20.4 Million USD | 8.52% |
| 1999 FY | -10.7 Million USD | 54.47% |
| 1999 Q3 | -18 Million USD | 11.76% |
| 1999 Q4 | -10.7 Million USD | 40.56% |
| 1999 Q1 | -22.3 Million USD | 5.11% |
| 1998 FY | -23.5 Million USD | 7.0% |
| 1998 Q3 | -24.3 Million USD | 0.82% |
| 1998 Q4 | -23.5 Million USD | 3.29% |
| 1998 Q2 | -24.5 Million USD | -18.36% |
| 1998 Q1 | -20.7 Million USD | 18.18% |
| 1997 Q4 | -25.3 Million USD | 3.44% |
| 1997 Q3 | -26.2 Million USD | -3.56% |
| 1997 Q2 | -25.3 Million USD | -8.58% |
| 1997 Q1 | -23.3 Million USD | 0.0% |
| 1997 FY | -25.27 Million USD | -461.56% |
| 1996 Q2 | -3.7 Million USD | -3800.0% |
| 1996 Q1 | 100 Thousand USD | 0.0% |
| 1996 FY | -4.5 Million USD | -21.62% |
| 1996 Q3 | -1.3 Million USD | 64.86% |
| 1995 Q3 | -300 Thousand USD | 91.89% |
| 1995 FY | -3.7 Million USD | -42.31% |
| 1995 Q1 | -1.5 Million USD | 6.25% |
| 1995 Q2 | -3.7 Million USD | -146.67% |
| 1995 Q4 | - USD | 100.0% |
| 1994 Q4 | -1.6 Million USD | 54.29% |
| 1994 FY | -2.6 Million USD | -966.67% |
| 1994 Q1 | -2.6 Million USD | 7.14% |
| 1994 Q2 | -2.6 Million USD | 0.0% |
| 1994 Q3 | -3.5 Million USD | -34.62% |
| 1993 FY | 300 Thousand USD | 30.43% |
| 1993 Q4 | -2.8 Million USD | -2900.0% |
| 1993 Q3 | 100 Thousand USD | 0.0% |
| 1992 FY | 230 Thousand USD | 53.33% |
| 1991 FY | 150 Thousand USD | 650.0% |
| 1990 FY | 20 Thousand USD | -94.59% |
| 1989 FY | 370 Thousand USD | 294.74% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1310.00 USD | 653000.763% |
| Arch Therapeutics, Inc. | 5.64 Million USD | -51.424% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 80.013% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 3526.408% |
| Rebus Holdings, Inc. | 305 Thousand USD | -2704.262% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 235.664% |
| Qrons Inc. | 351.42 Thousand USD | -2333.791% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 622.36 Thousand USD | -1274.276% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 80.308% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 42010.035% |
| Skye Bioscience, Inc. | -5.72 Million USD | 249.492% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 45.74% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | -107.697% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -2028.411% |
| SQZ Biotechnologies Company | -36.23 Million USD | 123.602% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | -281.45% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | -822.469% |
| Mesoblast Limited | 55.85 Million USD | 84.688% |
| Marizyme, Inc. | 18.56 Million USD | 53.939% |
| Genus plc | 190.6 Million USD | 95.513% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | -282.542% |
| Pharming Group N.V. | 109.8 Million USD | 92.211% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | -894.256% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | -604.595% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | -1157.794% |
| ContraFect Corporation | -6.02 Million USD | 241.935% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -6252.543% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | -640.245% |
| IMV Inc. | 7.67 Million USD | -11.505% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | -55.456% |
| MultiCell Technologies, Inc. | 90.04 USD | -9499011.506% |
| ONE Bio Corp. | 9.04 Million USD | 5.388% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 1265.294% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 33.933% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | -525.233% |
| Q BioMed Inc. | 4.06 Million USD | -110.665% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 72.007% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | -748.751% |
| Biomind Labs Inc. | 711.4 Thousand USD | -1102.274% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 85.873% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | -327.78% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 33.214% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -2277.749% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -6017.851% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -42951.291% |
| Curative Biotechnology, Inc. | 2.2 Million USD | -288.423% |
| GB Sciences, Inc. | 1.74 Million USD | -389.494% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 4753.731% |
| HST Global, Inc. | 96.79 Thousand USD | -8736.383% |
| CSL Limited | 10.52 Billion USD | 99.919% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | -4047.573% |
| Halberd Corporation | 144.72 Thousand USD | -5809.992% |
| Enzolytics Inc. | 981.65 Thousand USD | -771.283% |
| Agentix Corp. | 37.63 Thousand USD | -22628.601% |
| Resverlogix Corp. | 6.45 Million USD | -32.584% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 1370.709% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -2.02 Billion USD | 100.422% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 118.193% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | -20.959% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -215.77% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 196.754% |
| AVAX Technologies, Inc. | -5.9 Million USD | 244.887% |
| Zenith Capital Corp. | 10.06 Thousand USD | -84886.089% |
| Genscript Biotech Corporation | -1.06 Billion USD | 100.806% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | -4167.283% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | -258.461% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | -5099.108% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 46791.779% |
| Kadimastem Ltd | -253.1 Thousand USD | 3479.27% |
| Helix BioMedix, Inc. | -2.57 Million USD | 432.797% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 57.817% |
| BioStem Technologies, Inc. | 4.47 Million USD | -91.256% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | -4149.853% |
| LadRx Corporation | -2.03 Million USD | 519.992% |
| Cell Source, Inc. | 9.23 Million USD | 7.355% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -1246.575% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -1246.575% |
| NovAccess Global Inc. | 2.17 Million USD | -292.616% |
| Affymax, Inc. | -5.59 Million USD | 252.814% |
| Itoco Inc. | 228.3 Thousand USD | -3646.304% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -6189.479% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | -72.544% |
| Mobile Lads Corp. | 484.23 Thousand USD | -1666.302% |
| CytoDyn Inc. | 20.26 Million USD | 57.788% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 1322047.45% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 92381.897% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | -10.991% |
| SYBLEU INC | 473.71 Thousand USD | -1705.52% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | -91.899% |
| International Stem Cell Corporation | 2.59 Million USD | -230.232% |
| Bioxytran, Inc. | 1.89 Million USD | -350.415% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -13603.876% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -292.178% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | -149.068% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | -1007.031% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 784.24% |
| Neutra Corp. | 52.18 Thousand USD | -16289.139% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 443.632% |
| PureTech Health plc | -167.19 Million USD | 105.116% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 3592.332% |
| IXICO plc | -4.44 Million USD | 292.436% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 35.298% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 84.407% |
| CSL Limited | 10.52 Billion USD | 99.919% |
| Cellectis S.A. | -43.81 Million USD | 119.519% |